MedTrace Logo

Effect of Intra-Dialytic Muscle Energy Technique on Restless Leg Syndrome in Hemodialysis Patients

NCT07748065 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-05

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if intra-dialytic Muscle Energy Technique (MET) can reduce symptoms of restless legs syndrome (RLS) in people with end-stage renal disease (ESRD) receiving maintenance hemodialysis. The study also aims to learn if this treatment can improve sleep quality, muscle strength, blood pressure, and oxygen saturation.

The main questions it aims to answer are:

* Does intra-dialytic Muscle Energy Technique reduce the severity of restless legs syndrome?
* Does intra-dialytic Muscle Energy Technique improve sleep quality, muscle strength, blood pressure, and oxygen saturation?

Researchers compared people who received intra-dialytic Muscle Energy Technique together with routine medical treatment and hemodialysis with people who received routine medical treatment and hemodialysis alone to find out whether adding Muscle Energy Technique provides greater benefits.

Participants:

* Were randomly placed into one of two groups.
* Received routine medical treatment and hemodialysis.
* Received intra-dialytic Muscle Energy Technique during the second hour of hemodialysis if they were in the intervention group.
* Had three treatment sessions each week for eight weeks.
* Had assessments before and after the eight-week treatment.

Conditions

  • Restless Legs Syndrome (RLS)
  • End-Stage Renal Disease

Interventions

PROCEDURE

Muscle Energy Technique

Intra-dialytic Muscle Energy Technique (MET) was performed for 20 minutes during the second hour of maintenance hemodialysis, three sessions per week for eight weeks.

OTHER

Routine Medical Treatment and Hemodialysis

Routine medical treatment and maintenance hemodialysis without additional physical therapy intervention.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748065 on ClinicalTrials.gov